Loading clinical trials...

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients | Clinical Trials | Clareo Health

WITHDRAWNPHASE4

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

Bivalirudin PCI Registry in HIT/HITTS Patients

NCT00759083•The Medicines Company

View on ClinicalTrials.gov

Summary

To monitor the frequency of the development of thrombocytopenia in patients with Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome receiving bivalirudin during Percutaneous Coronary Intervention

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Clinically Documented History of HIT/HITTS
•Suspicion of HIT/HITTS

Exclusion Criteria

•Bleeding Diathesis
•Ischemic Stroke
•Chronic Thrombocytopenia
•Hematologic Malignancy
•Contraindication to bivalirudin
•Pregnant or nursing mothers

Locations (1)

Duke Clinical Research Institute

Durham, North Carolina, United States

Key Dates

Start Date

September 1, 2008

Primary Completion Date

September 1, 2009

Completion Date

May 10, 2010

Last Updated

October 19, 2020

Conditions

Heparin-Induced ThrombocytopeniaHeparin-induced Thrombocytopenia and Thrombosis Syndrome

Interventions

bivalirudin

DRUG

Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.

NCT06066762

Heparin-induced Thrombocytopenia

View study

UNKNOWN

Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery

NCT05783895

Heparin-induced Thrombocytopenia

View study

UNKNOWN

PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer

NCT04842760

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 19, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

Inclusion Criteria

Exclusion Criteria

Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.

Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery

PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer

Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban

Optimizing the Diagnosis of Heparin Induced Thrombocytopenia

Rapid Diagnosis of Heparin-Induced Thrombocytopenia in Surgical Critically Ill Patients